Abstract
Oral delivery of MA-[d-Leu-4]-OB3 has been shown to significantly improve energy balance, glycemic control, dyslipidemia, and episodic memory in mouse models of fully-expressed T1DM and T2DM. To assess the prophylactic capacity of MA-[d-Leu-4]-OB3 to prevent or slow the progression of obesity, insulin resistance, and cognitive dysfunction, 3- to 4-week old male C57BL/6J mice were placed on a high-fat diet immediately after weaning, and maintained on this diet, in the absence or presence of orally delivered MA-[d-Leu-4]-OB3, for 23 weeks. Control mice of the same age and sex were maintained on a low-fat diet. Body weight, caloric and water intake, glucose tolerance, and fasting blood glucose levels were measured. Episodic memory was evaluated by novel object recognition testing. In male C57BL/6J mice maintained on a high-fat diet since weaning, MA-[d-Leu-4]-OB3 (1) normalized body weight gain for the first 8 weeks of the study, and sustained a significant reduction throughout the remaining 15 weeks; (2) had no effect on caloric or water intake; (3) improved glucose tolerance within 4 weeks; (4) reduced fasting blood glucose to levels approaching or equivalent to those seen in control mice within 3 weeks; and (5) normalized episodic memory within 4 weeks. In addition to its therapeutic potential, MA-[d-Leu-4]-OB3 may have a prophylactic application to the prevention or progression of many of the dysfunctions associated with metabolic syndrome, Down Syndrome, Alzheimer’s disease (AD), and other AD-like cognitive impairments in humans.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Change history
07 July 2021
In Fig. 3, the size of the part figures (a) and (b) are made equal.
References
Anderson BM, Jacobson L, Novakovic NM, Grasso P (2017) Oral delivery of [d-Leu-4]-Ob3 and MA-[d-Leu-4]-OB3, synthetic peptide leptin mimetics, immunofluorescent localization in the mouse hypothalamus. Brain Res 1664:1–8. https://doi.org/10.1016/j.brainres.2017.03.020
Anderson BM, Hirschstein Z, Novakovic ZM, Grasso P (2020) MA-[d-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, mirrors the cognitive enhancing action of leptin in a mouse model of Type 1 Diabetes Mellitus and Alzheimer’s Disease-like cognitive impairment. Inter J Pep Res Ther 26:1243–1249. https://doi.org/10.1007/s10989-019-00929-w
Banks WA, DiPalma CR, Farrell CL (1999) Impaired transport of leptin across the blood-brain barrier in obesity. Peptides 20:1341–1345. https://doi.org/10.1016/s0196-9781(99)00139-4
Banks WA, Clever CM, Farrell CL (2000) Partial saturation and regional variation in the blood-to-brain transport of leptin in normal weight mice. Am J Physiol Endocrinol Metab 278:E1158–E1165. https://doi.org/10.1152/ajpendo.2000.278.6
Bevins RA, Besheer J (2006) Object recognition in rats and mice: a one-trial non-matching-to sample learning task to study recognition memory. Nat Protoc 1:1306–1311. https://doi.org/10.1038/nprot.2006.205
Chu DT, Malinowska E, Jra M, Kozak LP (2017) C57BL/6J mice as a polygenic developmental model of diet-induced obesity. Physiol Rep 5:1–20. https://doi.org/10.14814/phy2.13093
Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JFl (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Eng J Med 334:292–295. https://doi.org/10.1056/NEJM199602013340503
Coppari R, Bjorback C (2012) Leptin revisited: its mechanism of action and potential for treating diabetes. Nature Rev Drug Disc 11:692–708. https://doi.org/10.1038/nrd3757
Cukierman T, Gerstein HD, Williamson JD (2005) Cognitive decline and dementia in diabetes—systemic overview of prospective observational studies. Diabetologia 48:2460–2469. https://doi.org/10.1007/s00125-005-0023-4
Dutta D, Ghosh S, Pandit K, Mukhopadhyay P, Chowdhury S (2012) Leptin and cancer: pathogenesis and modulation. Indian J Endocrinol Metab 16:S596–S600
El-Haschimi K, Pierroz DD, Hileman SM, Bjoprbek C, Flier JS (2000) Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest 105:1827–1832. doi 10.1172/JCI9842
Elsinger K, Liebisch G, Schmitz G, Aslanidis C, Krautbauer S, Beuchler C (2014) Lipidomic analysis of serum from high fat diet induced obese mice. Int J Mol Sci 15:2991–3002. doi 10.3390/ijms15022991
Francisco V, Pino J, Campos-Calbaleiro V, Ruiz-Femanez C, Mera A, Gonzaliez-Gay MA, Gomez R, Gualillo O (2018) Obesity, fat mass and immune system: role for leptin. Front Physiol 9:640. https://doi.org/10.3389/fphys.2018.00640
Garafalo C, Surmacz E (2006) Leptin and cancer. J Cell Physiol 207:12–22. https://doi.org/10.10002/jcp.20472
Harvey J (2010) Leptin: the missing link in Alzheimer disease? Clin Chem 56:696–697. https://doi.org/10.1373/clinchem.2010.144006
Hirschstein Z, Novakovic ZM, Grasso P (2020a) MA-[d-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, normalizes glucose tolerance and episodic memory in a mouse model of Type 2 diabetes Mellitus and Alzheimer’s Disease-like cognitive impairment. Inter J Pep Res Ther. https://doi.org/10.1007/s10989-019-09995-0
Hirschstein Z, Reddy Vanga G, Wang G, Novakovic ZM, Grasso P (2020b) MA-[d-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, improves episodic memory, and reduces serum levels of tumor necrosis factor-alpha and neurodegeneration in mouse models of Type 1 and Type 2 Diabetes Mellitus. BBA-Gen Sub 1864:129697. https://doi.org/10.1016/j.bbagen.2020.129697
Hirschstein Z, Wang A, Anderson BM, Novakovic ZM, Grasso P (2021) MA-[d-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, improves lipid profiles in mouse models of Type 1 and Type 2 Diabetis Mellitus. Int J Pep Res Ther. https://doi.org/10.1007/s10989-020-10155-y
Ho Y, Wang S-H, Chen Y-R, Li Z-L, Chin Y-T, Yang Y-H, Wu Y-H, Su K-W, Chu H-R, Chiu H-C, Crawford DR, Shis Y-J, Grasso P, Tang H-Y, Lin H-y, Davis PJ, Whang-Peng J, Wang K (2019) Leptin-derived peptides block leptin-induced proliferation by reducing expression of pro-inflammatory genes in hepatocellular carcinoma cells. Food Chem Toxicol 133:110808. https://doi.org/10.1016/j.fct.2019.110808
Novakovic ZM, Leinung MC, Grasso P (2010) Oral delivery of mouse [d-Leu-4]-OB3, a synthetic peptide with leptin-like activity, in male C57BL/6J wild-type and ob/ob mice: effects on energy balance, glycemic control, and serum osteocalcin levels. Diabetes Obes Metab 12:532–539. https://doi.org/10.1111/j.1463-1326.2009.01189.x
Novakovic ZM, Anderson BM, Grasso P (2014) Myristic acid conjugation of [d-Leu-4]-OB3, a biologically active leptin-related synthetic peptide amide, significantly improves its pharmacokinetics and efficacy. Peptides 62:176–182. https://doi.org/10.1016/j.peptides.2014.10.007
Pal K, Mukadam N, Petersen I, Cooper C (2018) Mild cognitive impairment and progression to dementia in people with diabetes, prediabetes and metabolic syndrome: a systemic review and meta-analysis. Soc Psychiatry Psychiatr Epidemiol 53:1149–1160. https://doi.org/10.1007/s00127-018-1581-3
Stewart R, Liolitsa D (1999) Type 2 diabetes Mellitus, cognitive impairment, and dementia. Diabetes Med 16:93–112. https://doi.org/10./j.1464-5491.19999.00027.x
Wang A, Anderson BM, Novakovic ZM, Grasso P (2018) [d-Leu-4]-OB3 and MA-[d-Leu-4]-OB3, small molecule synthetic peptide leptin mimetics, improve glycemic control in diet-induced obese (DIO) mice. Peptides 101:51–59. https://doi.org/10.1016/j.peptides.2017.12.012
Yang Y-C, Chin Y-T, Hsieh M-T, Lai H-Y, Ke C-C, XCrawford DR, Lee OK, Fu E, Mousa SA, Grasso P, Liu LF, Chang H-Y, Tang H-Y, Lin H-Y, Davis PJ (2016) Novel leptin OB3 peptide-induced signaling and progression in thyroid cancers: comparison with leptin. Oncotarget 7:2764–27654. https://doi.org/10.18632/onxcotarget.8505
Yin H, Tian S, Huang R, Cai R, Guo D, Lin H, Wang J, Wang S (2018) Low plasma leptin and high soluble leptin receptor levels are associated with mild cognitive impairment in type 2 diabetic patients. Front Aging Neurosci 10:132. https://doi.org/10.3389/fnagi.2018.00132
Acknowledgements
This work was supported by a grant from the Willard B. Warring Memorial Fund, Albany Medical College, Albany, NY, USA (P.G.). The Intravail® reagent was graciously provided by Aegis Therapeutics, San Diego, CA, USA.
Author information
Authors and Affiliations
Contributions
FYC: Data curation; investigation; methodology; software; writing—review and editing. ZMN: Conceptualization; writing—review and editing. PG: Conceptualization; formal analysis; funding acquisition; project administration; supervision; validation; visualization; resources; writing—original draft; writing—review and editing.
Corresponding author
Ethics declarations
Conflict of interest
Fu Yee Chua, Zachary Novakovic and Patricia Grasso declared that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which they were conducted: Albany Medical College Institutional Animal Care and Use Committee, Animal Care and Use Protocol #19-10002.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Chua, F.Y., Novakovic, Z.M. & Grasso, P. Prophylactic Application of MA-[d-Leu-4]-OB3, a Small Molecule Synthetic Peptide Leptin Mimetic, Prevents or Slows the Progression of Obesity, Insulin Resistance, and Cognitive Impairment in a Mouse Model of Type 2 Diabetes Mellitus. Int J Pept Res Ther 27, 2223–2230 (2021). https://doi.org/10.1007/s10989-021-10248-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10989-021-10248-2